Rennova Health, Inc. RNVA
At closeNov 3, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 4.31M
- Revenue (ttm)
- 3.12M
- Shares out
- 1.36M
- Forward P/E
- -0.05
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 497.85K
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
- Beta
- -1.29
- Price target
- 555.00 (+554999900.0%)
- Earnings date
- May 20, 2024
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 18.56M
- PEG ratio
- 0.00
- Price / sales
- 0.06
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -65.00%
- Free cash flow
- -11.26M
- Total cash
- 27.70K
- Total debt
- 15.08M
- Return on equity
- 0.00%
- Short % of float
- 20.62%
- 50-day average
- 0.887778
- 200-day average
- 4.21
Analyst view
Next earnings
May 20, 2024
Expected May 20, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 20, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
About Rennova Health, Inc.
Rennova Health, Inc., together with its subsidiaries, provides a suite of healthcare related products and services to healthcare providers in the United States. The company operates in three segments: Laboratory Services, Supportive Software Solutions, and Decision Support and Informatics Operations. It provides toxicology, clinical pharmacogenetics, and esoteric testing services. The company also offers Advantage, a HIPAA compliant software; Clinlab, a Windows-based Web-enabled laboratory information management system; and Medical Mime, a suite of solutions, which include an optimized Electronic health records (EHR) for substance abuse and behavioral health providers, a dictation-based ambulatory EHR for physician practices, and advanced transcription services. In addition, it develops and markets interpretation and decision support solutions that enhance cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients. Rennova Health, Inc. was founded in 2005 and is headquartered in West Palm Beach, Florida.
- Country
- United States
- Website
- rennovahealth.com
News
Analyzing Rennova Health (OTCMKTS:RNVA) & HeartSciences (NASDAQ:HSCS) 
Financial Comparison: Tivic Health Systems (NASDAQ:TIVC) versus Rennova Health (OTCMKTS:RNVA) 
Analyzing Rennova Health (OTCMKTS:RNVA) & Nyxoah (NASDAQ:NYXH) 
Contrasting Rennova Health (OTCMKTS:RNVA) & Movano (NASDAQ:MOVE) 
RENNOVA HEALTH, INC., ANNOUNCES THE EXPIRATION OF WARRANTS TO PURCHARE OVER FOUR HUNDRED BILLION COMMON SHARES 
RENNOVA HEALTH, INC. CEO PROVIDES JANUARY 2024 MESSAGE TO SHAREHOLDERS 
RENNOVA HEALTH, INC. ANNOUNCES SIGNIFICANT DEBT RESTRUCTURING 
RENNOVA HEALTH, INC. PROVIDES UPDATE AFTER FILING 2023 SECOND QUARTER FINANCIAL STATEMENTS 
RENNOVA HEALTH, INC. ANNOUNCES THE OPENING OF ITS FIRST ALCOHOL AND DRUG TREATMENT FACILITY 
RENNOVA COMPLETES AGREEMENT TO SEPARATE ITS SOFTWARE AND GENETIC DIAGNOSTICS INTERPRETATION DIVISIONS INTO INNOVAQOR, INC. (OTC: INOQ) [UPDATED]
Your note
Sign in to keep a note on RNVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AJAMI KAMRAN | Director | Acquisition (Non Open Market) | Aug 14, 2017 | 100,000 |
| DIAMANTIS CHRISTOPHER ERIC | Director | Acquisition (Non Open Market) | Aug 14, 2017 | 100,000 |
| LAGAN SEAMUS | Officer | Acquisition (Non Open Market) | Aug 14, 2017 | 200,000 |
| LANGLEY TREVOR | Director | Acquisition (Non Open Market) | Aug 14, 2017 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 13.85% | 466,880 | 1.33M | Sep 29, 2017 |
| Two Sigma Securities, LLC | 2.85% | 96,060 | 273.77K | Sep 29, 2017 |
| Virtu Financial LLC | 1.59% | 53,475 | 152.40K | Sep 29, 2017 |
| UBS Group AG | 0.99% | 33,277 | 94.84K | Sep 29, 2017 |
| Bank Of New York Mellon Corporation | 0.90% | 30,353 | 86.51K | Sep 29, 2017 |
| Guggenheim Capital, LLC | 0.53% | 17,820 | 50.79K | Sep 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.02% | 619 | 3.16K | Jul 30, 2017 |